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Abstract Despite all available therapies, the rates of
hospitalization and death from heart failure (HF) remain
unacceptably high. The most common reasons for hospital
admission are symptoms related to congestion. During
hospitalization, most patients respond well to standard
therapy and are discharged with significantly improved
symptoms. Post-discharge, many patients receive diligent
and frequent follow-up. However, rehospitalization rates
remain high. One potential explanation is a persistent
failure by clinicians to adequately manage congestion in
the outpatient setting. The failure to successfully manage
these patients post-discharge may represent an unmet need
to improve the way congestion is both recognized and
treated. A primary aim of future HF management may be to
improve clinical surveillance to prevent and manage
chronic fluid overload while simultaneously maximizing
the use of evidence-based therapies with proven long-term
benefit. Improvement in cardiac function is the ultimate
goal and maintenance of a ‘‘dry’’ clinical profile is
important to prevent hospital admission and improve
prognosis. This paper focuses on methods for monitoring
congestion, and strategies for water and sodium management
in the context of the complex interplay between the cardiac
and renal systems. A rationale for improving recognition and
treatment of congestion is also proposed.
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Introduction
Despite all available therapies, there are over one million
hospitalizations for heart failure (HF) annually in the USA
alone [1], and a similar number in Europe. Symptoms
responsible for hospitalization are typically related to
pulmonary or systemic congestion that result in dyspnea,
rales and edema [2]. Growing evidence suggests that con-
gestion itself leads to HF progression [3]. Owing to exerts
detrimental effects on the heart (altered ventricular geom-
etry, functional mitral insufficiency, further increase in
intra-cardiac pressures) and other organs (kidneys and
liver) via increased venous pressures [4]. Congestion,
ideally, should be prevented and its early detection, pos-
sibly with the help of new technologies, may allow for
early intervention long before overt symptoms develop.
Current therapies for congestion should be personalized
according to congestion severity and renal function, and
should be used to ‘‘bridge’’ patients through episodes of
worsening congestion, while providing opportunities to add
proven therapies that improve cardiac function and out-
comes. In this respect, this paper will focus on (1) methods
for monitoring congestion and related kidney injury; (2)
strategies for fluid and sodium management; and (3) the
rationale for improved recognition and treatment of con-
gestion with the goal of improving HF outcomes.
Congestion in Heart Failure
Congestion is a manifestation of several concurrent pro-
cesses both structural and functional including ventricular
remodeling, progression of coronary artery disease, val-
vular abnormalities, neurohormonal and inflammatory
activation, vascular adaptations and renal dysfunction [5].
It is often not recognized until it becomes severe enough to
necessitate hospital admission or acute therapies in diverse
settings. It can be divided into two general categories that
represent a continuum; hemodynamic and clinical con-
gestion [6]. Hemodynamic congestion refers to the state of
increased intra-cardiac filling pressures accompanied by
cardiopulmonary volume overload that can occur in the
absence of clinically evident signs/symptoms. Clinical
congestion refers to the presence of signs/symptoms related
to elevated intra-cardiac filling pressures. These pressures
may begin to rise days to three weeks prior to the devel-
opment of symptoms or weight gain [7]. Some studies have
suggested that in patients with pulmonary congestion, fluid
overload is caused by fluid redistribution because of an
increased vascular resistance/stiffness which may lead to
both reduced capacitance in the large veins and increased
arterial resistance with consequent endogenous fluid shift
from splanchnic bed into effective circulating volume
rather than on endogenous fluid gain. Fluid redistribution
and fluid accumulation may be variably combined in such
patients [8]. However, aside from this potential redistri-
bution, true accumulation of fluid due to sodium and water
retention secondary to adaptative neurohormonal changes
is also at play. Congestion can increase LV wall stress,
functional mitral regurgitation and neurohormonal/inflam-
matory activation, thus exacerbating myocardial remodel-
ing (chamber dilatation, increased ventricular sphericity
and aggravated ischemia), loss of myocardial cells,
decreasing ventricular function and leading to worsening
hemodynamics and progressive HF (Fig. 1). LV impair-
ment often leads to right ventricular (RV) dysfunction
either through ventricular interdependence or because of
chronically elevated left-sided filling pressures that lead to
an increase in pulmonary pressures which in turn affects
RV afterload. This increase in RV afterload (pulmonary
venous hypertension extends to pulmonary arteries) leads
to RV dysfunction, tricuspid regurgitation, and subsequent
further RV impairment and systemic congestion, reinforc-
ing the vicious cycle of HF (Fig. 2). Conversely, systemic
congestion increases RV preload that in long term leads to
RV dysfunction, tricuspid incompetence and increased
right-side filling pressure. The result is the increased cen-
tral venous pressure with subsequent renal dysfunction and
further congestion. Thus, the concept of hemodynamic
congestion illustrates that hemodynamic derangements can
substantially precede clinical manifestations and that
careful detection of hemodynamic congestion allows a
window for early preclinical intervention (Fig. 1).
Clinicians are likely failing to recognize and treat con-
gestion because of the insidious onset with which it
develops. Furthermore, the clinical evaluation of volume
overload is limited. In ambulatory non-edematous patients
with HF, clinically unrecognized hypervolemia (as deter-
mined by blood volume analysis) is frequently present and
associated with increased cardiac filling pressures and
worse patient outcomes [9]. Once congestion is detected, it
is an obvious target for therapy. Aggressive reduction of
intra-cardiac filling pressures is beneficial by producing
symptom relief with concomitant improvements in mitral
regurgitation, RV function, neurohormonal activation and
exercise tolerance. Often, however, congestion is inade-
quately treated and patients are often discharged with
residual elevation in circulating volume and symptoms that
are improved but not resolved. This contributes to insta-
bility and readmission early after discharge [10].
Congestion Assessment
The ‘‘gold standard’’ for evaluating congestion in hospi-
talized patients is the measurement of pulmonary capillary
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wedge pressure (PCWP) that closely approximates LV end-
diastolic pressure. However, PCWP measurement involves
invasive catheterization, limiting its clinical use. Body
weight monitoring is readily available, but is often not
representative of changes in filling pressures [10]. Clinical
assessment of jugular venous pressure remains the most
sensitive and specific test for detecting elevated LV filling
pressures. Campbell et al. [11] provide reassurance that
concordance of elevated right- and left-side filling pres-
sures allows reliance upon jugular venous assessment in
majority of patients with chronic HF. However, when
therapy guided by right-sides assessment does not produce
Fig. 1 Pathophysiological
course and vicious cycle of HF
until clinical congestion,
including renal dysfunction by
cardio-renal interaction,
subdivided in phases of
preclinical medical
interventions and
hospitalization, suggesting a
window for earlier intervention
on hemodynamic congestion
Fig. 2 The vicious cycle of HF
progression with mutual
involvement of left and right
sides of the heart and the
kidney: key role of congestion
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the desired responses, consideration should be given to
invasive measurement of left-side filling pressures. Fur-
thermore, other physical findings such as rales and
peripheral edema can be absent in a large proportion of
patients despite measured intravascular volume overload.
Therefore, new technologies that supplement clinical
evaluation are required for monitoring fluid overload in
HF. Chest radiography can demonstrate chronically ele-
vated filling pressures but does not change rapidly enough
to guide acute evaluation and therapy. Efforts to improve
clinical monitoring have included scoring systems. One
such system, which contains the variables of pulmonary
crackles, pathological jugular venous distention, peripheral
edema and third heart sound, results in a 95 % negative
predictive value for left atrial pressure \20 mmHg [12].
Plasma natriuretic peptides (NP) were first used with the
promise of increasing the diagnostic accuracy of HF,
diagnosing elevated LV filling pressures and defining
‘‘congestion’’. However, NP should not be used alone to
assess congestion but must be evaluated in the appropriate
clinical context because there is no defined cut-point and
their pattern of production and release is slow and variable.
However, having a baseline NP concentration may help
determine a patient’s ‘‘target’’ level and may be helpful to
monitor filling pressure and to optimize therapy.
New noninvasive instrumental methods for congestion
assessment include:
(1) Ultrasonography of the inferior vena cava (IVC), a
rapid method to estimate elevated right atrial pressure
by measuring IVC diameter and its collapsibility;
(2) Echocardiographic assessment of PCWP or LV
filling pressure estimated by trans-mitral E/e1 the
ratio of peak early mitral flow velocity (E) divided
by mitral annular early diastolic velocity (e1),
measured by Tissue Doppler Imaging;
(3) Lung ultrasound for detecting B lines (also called
ultrasound lung comet), which correlate with a
radiographic score of pulmonary congestion and
invasively measured extravascular lung water values
[13] (Table 1);
(4) Transthoracic bioimpedance or thoracic impedance
cardiography which utilizes the principle that electrical
impedance is specifically and inversely correlated with
the content of tissue fluids. It provides an assessment of
cardiac output and stroke volume, systemic vascular
resistance and thoracic fluid content (Fig. 3).
Several studies have shown that decreasing thoracic
impedance correlates with HF hospitalizations. Similarly,
some studies indicate that new noninvasive methods that
detect whole-body bioelectrical impedance are capable of
rapidly assessing intra- and extra-cellular total body fluid
content (overhydration or dehydration) and the effective-
ness of diuresis [14]. These methods, however, require
large trials to confirm clinical utility.
Cardio-renal Interaction in Heart Failure
The ADHERE registry revealed high prevalence of renal
dysfunction in acute HF patients. In particular, moderate
Table 1 Main cutoff of noninvasive methods of congestion monitoring according to heart failure clinical profile
Parameters Wet profile Dry profile
IVC collapse index \50 % ? RAPs [10 mmHg [54] C50 % ? RAPs B10 mmHg
\45 % ? RAPs [8 mmHg [55] [45 % ? RAPs B8 mmHg
\40 % ? RAPs [10 mmHg [56] [40 % ? RAPs B10 mmHg
IVC max expiratory diameter C2 cm \2 cm
B1.2 cm are indicative of normal
RAPs (B10 mmHg) at 100 % [57]
Echocardiographic PCWP [12 [58] B12
E/e1 (a) C15 (Sep.); C 12 (Lat.); C 13 (Av.) [59] \15 (Sep.); \12 (Lat.); \13 (Av.)
C11 [60] \11
B8 (sep, lat, or Av.) indicates very low
LV filling pressure
Lung ultrasound Multiple bilateral B lines assessed on the anterior and
lateral chest: two or more positive regions bilaterally
(a positive region is defined by the presence of C3
ultrasound B lines in a longitudinal plane between two
ribs) [61]
B2 ultrasound B lines in any chest region
Sep septal, Lat lateral, Av average, RAP right arterial pressure
a E/e1 ratio ranging from 9 to 14 is a gray zone considered suggestive but non-diagnostic of diastolic LV dysfunction and needs to be
implemented with other noninvasive investigations to confirm the diagnosis of HF
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(GFR 30–59 ml/min/1.73 m2) and severe renal dysfunction
(GFR 15–29 ml/min/1.73 m2) and kidney failure (GFR \
15 ml/min/1.73 m2) occurs in 43.5 %, 13.1 % and 7.0 %
respectively [15]. Additionally, in patients with HF, an acute
or chronic reduction in glomerular filtration rate (GFR) has
been independently associated with poor outcomes [16, 17].
Cardio-renal interactions can be divided into five categories
based on the classification of Ronco et al. [18]. The first two
include the forms where the heart is the primary failing organ:
type 1 occurs when acute HF leads to acute kidney injury and
type 2 refers to chronic HF causing progressive and poten-
tially permanent chronic kidney disease (CKD). This is much
more useful than the initial use of the term cardio-renal syn-
drome which referred only to WRF which occurs during
therapy to relieve congestive HF symptoms. The patho-
physiology of HF-related renal dysfunction remains com-
plex. Multiple mechanisms are likely involved [19],
including: (1) reduced cardiac output (CO) and renal perfu-
sion; (2) elevated central venous pressure (CVP); (3) elevated
intra-abdominal pressure (defined as[8 mmHg); (4) activa-
tion of inflammatory and neurohormonal systems and oxi-
dative stress; (5) preexisting chronic renal disease; and (6)
drug mediated diuretics, antibiotics, NSAIDs. A failing heart
is unable to generate adequate ‘‘forward’’ CO, leading to pre-
renal hypoperfusion and arterial underfilling with compen-
satory neurohormonal activation including the renin–angio-
tensin–aldosterone system (RAAS), sympathetic nervous
system and arginine vasopressin (AVP) expression [19]. In
the presence of diminished CO and low systemic pressures,
the kidney itself can maintain adequate renal perfusion by
means of autoregulatory mechanisms [20]. Neurohumoral
activation may be useful during acute stress to help restore
CO and preserve renal perfusion and filtration fraction by
increasing circulating volume. Chronic volume retention,
however, can lead to a vicious cycle in which increased pre-
load and afterload can further diminish CO. In parallel, per-
sistent renal hypoperfusion may lead to chronic renal
hypoxia, inflammation and oxidative stress causing progres-
sive renal dysfunction. Improvements in cardiac index (CI)
alone may not, however, result in improved renal function, as
supported by the ESCAPE trial where, of the hemodynamic
parameters measured, only right atrial pressure (a surrogate
for venous congestion) was correlated with baseline renal
dysfunction [21]. Similarly, Mullens et al. [22] found WRF
during hospitalization (serum creatinine increase [0.3 mg/
dL) to be associated with higher central venous pressure on
admission and discharge and they failed to demonstrate an
association with lower cardiac index. RV dysfunction and
tricuspid regurgitation have an important role in this process,
as reflected by the ability of CVP to stratify risk across various
levels of cardiac index. This is also supported by improved
renal outcome after relief of venous congestion. These find-
ings are consistent with the hypothesis that elevated CVP can
be transmitted back on the renal veins with subsequent
Fig. 3 Key points of
congestion assessment
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increased renal interstitial pressure. This may lead to impaired
GFR and hypoxic damage similar to congestive liver dys-
function in HF. An increase in hydrostatic pressure in Bow-
man’s capsule and afferent arteriolar vasoconstriction can
result in reduction in GFR independent of CO [23]. Intrarenal
vasoconstriction may result from sympathetic and neurohor-
monal stimulation. Moreover, venous congestion, through
stretch of endothelial cells, can modulate the synthetic and
endocrine phenotype of the vascular endothelium from a
quiescent state to an activated one, leading to a pro-oxidant,
pro-inflammatory and vasoconstrictive state. This may con-
tribute to the development and progression of functional or
structural changes in the kidneys (in particular in the tubulo-
interstitium) with subsequent sodium and water retention [24].
Pharmacotherapies used in the management of HF may
worsen renal function: diuresis associated hypovolemia, early
introduction of RAAS blockade, and drug-induced hypoten-
sion have all been suggested as contributing factors. In par-
ticular, hemoconcentration in subjects aggressively treated
with diuretics is significantly associated with deterioration in
renal function, but 180-day mortality was reduced in these
subjects, when compared to subjects treated more conserva-
tively. WRF may therefore be acceptable upon start of therapy
with diuretics [25] as well as with angiotensin-converting
enzyme inhibitors. It should be noted that impairment of renal
function is as likely to occur as improvement during diuresis
for hypervolemia in chronic HF.
Kidney Injury and Biomarkers
Acute kidney injury (AKI) is a common complication in
patients hospitalized for acute HF and has been associated
with longer hospitalization and increased morbidity and
mortality. It occurs as a consequence of new onset kidney
injury or acute deterioration of preexisting chronic kidney
disease (CKD) (acute-on-chronic kidney injury). AKI was
defined by the Acute Kidney Injury Network (AKIN) criteria
as an abrupt (within 48 h) reduction in kidney function with as
an absolute increase in serum creatinine [0.3 mg/dl
(C26.4 lmol/L), a percentage increase in serum creatinine
[50 % or a reduction in urine output\0.5 ml/kg per hour for
more than 6 hours [26]. More recently, the Kidney Disease
Improving Global Outcomes (KDIGO) group has refined this
definition to be an increase in serum creatinine[50 % within
7 days, or an increase in serum creatinine [0.3 mg/dl
(26.5 lmol/L) within 2 days, or oliguria. Damman et al. [27]
have reported a 61 % increase in the risk of death and a 30 %
increase in the risk of all-cause readmissions, when there was
AKI after 2–6 months of follow-up. Serum creatinine is not
always a reliable indicator of early kidney injury. Serum
creatinine varies with age, gender, ethnicity, muscle mass and
volume status. Furthermore, changes in serum creatinine may
reflect hemodynamic factors without any associated tubular,
vascular or interstitial injury. Traditionally, GFR remains the
gold standard for assessing renal function. However, mea-
suring accurate real time GFR remains difficult in the clinical
setting. Formulas estimating GFR have been validated when
serum creatinine is in a steady state and thus are not accurate
during acute changes in renal function. Conversely, blood
urea nitrogen, has recently been emerged as a stronger pre-
dictor of outcome than creatinine and estimated GFR rep-
resents an emerging surrogate marker for the ‘‘renal
response’’ to neurohormonal activation and congestion. Of
the many new biomarkers available, serum and/or urine
neutrophil gelatinase-associated lipocaptin (NGAL), serum
cystatin C, kidney injury molecule 1 (KIM-1) and N-acetyl-
beta-D-glucosaminidase (NAG) appear to be the most
promising panel of biomarkers for renal tubular injury and/or
functional assessment. A recent study demonstrated that
tubulo-interstitial damage detected by measuring urinary
NAG, KIM-1 NGAL, was associated with an adverse prog-
nosis in HF patients even when GFR was normal [28].
Another study found that KIM-1 and NAG were predictive of
all-cause mortality and the composite of all-cause mortality
and rehospitalization for HF, whereas NGAL was not asso-
ciated with either outcome [29]. Furthermore, Damman et al.
[30] showed that in CHF patients, urinary NAG, but not
NGAL or KIM-1 correlated with GFR (r = -0.34, p =
0.001) and effective renal plasma flow (r = -0.29, p =
0.006). Both NAG (r = 0.21, p = 0.048) and KIM-1 (r =
0.23, p = 0.033) correlated with plasma N-terminal pro-
brain natriuretic peptide levels. Furthermore, both urinary
NAG (HR = 1.42, p = 0.039) and KIM-1 (HR = 1.15,
p = 0.025) were associated with an increased risk of death or
HF hospitalizations, independent of GFR. Importantly, a
recent study on subclinical modulation of volume status found
that diuretic withdrawal resulted in significant increases in
urinary KIM-1, and NAG while NGAL and serum creatinine
were unaffected [31]. After reinstitution of furosemide treat-
ment, both urinary KIM-1 and NAG concentrations returned
to baseline, but NGAL was unaffected. These results suggest
that subclinical alterations in volume status in HF patients are
associated with changes in markers of renal tubular dysfunc-
tion and that diuretic therapy may favorably affect renal
tubular function by decreasing congestion. All these findings
suggest an important future role for markers of renal tubular
damage to monitor cardio-renal interaction in HF.
From Low-Dose to High-Dose Loop Diuretics: Flexible
Titration
Diuretics remain the mainstay of treatment in 90 % of HF
patients hospitalized with worsening HF in the USA and
Europe [32]. The relationship between diuretic delivery and
18 Heart Fail Rev (2015) 20:13–24
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response is characterized by a sigmoidal dose response curve
where efficacy (maximal effect) is the same for all loop
diuretics. Several features of this pharmacodynamic rela-
tionship are clinically important. First, there is a threshold
drug concentration which must be achieved at the active site
to elicit a response, and this threshold differs from patient to
patient. Clinically, this means that patients should have doses
tailored to their individual needs. Second, a maximal
response can be identified, allowing a definition of the ceiling
dose of a diuretic, namely, the smallest dose of a diuretic
eliciting a maximal response and, therefore, the dose that
should not be exceeded. In patients with renal insufficiency,
the plasma half-life of furosemide is prolonged because both
urinary excretion and renal conjugation are decreased. When
sufficient doses are administered to attain effective amounts
of loop diuretic in the urine, the diuretic response in func-
tional nephrons is the same in patients with renal insuffi-
ciency as in healthy volunteers. However, a response in terms
of total urinary sodium excretion never reaches that of a
healthy volunteer because the decrease in renal function
limits filtered sodium. Clinically, this means that a maxi-
mally effective dose of a loop diuretic in a patient with renal
insufficiency may not result in the required overall diuresis
and that other measures, including high doses, frequent
dosing, combining diuretics, may also need to be employed.
In HF patients, the quantity of furosemide absorbed is
the same of healthy subjects but the absorbtion is slowed.
The sigmoidal dose–response curve is shifted downward
and rightward [33], resulting in a natriuretic response that
is one-fourth to one-third of what occurs normally with
maximally effective doses of loop diuretics. In HF, chronic
treatment with loop diuretic is associated with intrarenal
resistance that may be initially overcome by larger doses of
furosemide. Alternative, therapeutic strategy is to admin-
ister modest doses more frequently, combine different class
of loop diuretic or add a thiazide. This last strategy may
have a synergistic response with profound diuresis.
In summary, a patient who has renal insufficiency
should be given increasing doses of a loop diuretic until
an effective dose is found or the ceiling dose relative to
the individual patient’s renal function is reached. In
patients with congestive HF and preserved renal func-
tion, delivery of loop diuretics to the tubular fluid is
normal [34]. Given that the pharmacokinetics of loop
diuretics are essentially normal in patients with HF, it
can be said that pharmacodynamic mechanisms associ-
ated with enhanced proximal sodium reabsorption in the
nephron account for a diminished response. Felker et al.
[35] in a prospective randomized trial in ADHF,
observed that global assessment of symptoms or changes
in renal function not differ significantly when diuretic
therapy was administered by bolus as compared with
continuous infusion or at high dose as compared with a
low dose. The high-dose strategy was associated with a
greater diuresis and more favorable outcomes in some
secondary measures but also with transient worsening of
renal function [35].
Regarding diuretic titration, several sets of HF consensus/
guideline statements support the use of a flexible diuretic
dosing regimen for outpatient management of fluid overload-
related signs and symptoms. The rationale is to titrate the
diuretic increasing or reducing doses according to the state of
congestion, the symptoms or the possible risk of excessive
volume depletion. Today, only five randomized studies have
evaluated this issue in HF. Three randomized trials included
flexible diuretic titration as part of a broader multifaceted
disease management program, and 2 were designed to spe-
cifically evaluate the sole contribution of flexible diuretic
titration. Collectively, data from these studies supported the
idea that flexible and individualized diuretic dosing is
potentially associated with reduced emergency room visits,
reduced rehospitalization, and improved quality of life in HF
patients with reduced ejection fraction [36].
Improving Post-Discharge Outcomes
Despite multiple trials aimed at improving outcomes,
patients hospitalized with HF face mortality and rehospi-
talization rates as high as 15 and 30 % within 60–90 days
post-discharge, respectively [37]. Results from the
ESCAPE trial demonstrate associations between conges-
tion and clinical course with patients who continue to have
a ‘‘wet’’ profile after acute HF treatment, showing a sig-
nificantly increased risk of adverse outcomes at 6 months
compared with those who are ‘‘dry’’ at discharge [10].
Contributing factors to this unacceptably high post-dis-
charge event rate include the incomplete relief of fluid
overload, insufficient patient education, the lack of
implementation of evidence-based therapies and poor post-
discharge follow-up [38]. The transition from the hospital
to the outpatient setting involves not only changes in the
physicians providing care, but also modifications in diet,
self-dependence in the administration of new and complex
drug therapies, demands for more physical activity, and
confrontation with familial and social stresses [39].
Moreover, patients are often discharged not only before
optimal volume status is achieved, but also without ade-
quate control of their blood pressure or with an inadequate
ventricular response to atrial fibrillation. All of these fac-
tors make the early post-discharge period a vulnerable
phase which require, for all these considerations, clinical
surveillance [37]. Most patients leave the hospital with
relative symptomatic improvement but without complete
optimization of filling pressures and with an optimistic, but
perhaps unrealistic plan for physicians to ‘‘continue
Heart Fail Rev (2015) 20:13–24 19
123
diuresis at home’’. The recent COMPASS-HF study [40],
enabling continuous monitoring of RV and estimated pul-
monary artery diastolic pressures in patients with recent HF
hospitalizations has shown how high the daily filling
pressures remained elevated despite apparently intensive
management, how slowly the filling pressures rose prior to
HF decompensation events, and how poorly body weight
reflected changes in filling pressures during extended out-
patient follow-up [10]. Excluding the periods around
events, the risk of subsequent HF events was clearly and
continuously related to the level of chronic median filling
pressures, with no threshold or shoulder level once the
median daily pressure exceeded 14 mm Hg.
Post-discharge assessment is now deemed an essential
component of the treatment of the patients hospitalized for
HF to promote recovery and good health. The aim is to
maintain lower filling pressures, relieve symptoms, improve
exercise tolerance, decrease neurohormonal activation and
reduce morbidity and mortality [10]. Simply decreasing
body weight cannot be used as an indiscriminate target for
reducing hospitalization events [41]. In a small observa-
tional study, physician-directed patient self-management of
HF with direct left atrial pressure (LAP) monitoring was
associated with improved LAP control, reduced symptoms,
more optimal neurohormonal antagonist and diuretic dosing,
hemodynamic remodeling and a reduction of early clinical
events [42]. These data indicate that outpatient hemody-
namic monitoring linked to a self-management therapeutic
strategy could change current management of advanced HF
and potentially facilitate more optimal therapy and improve
outcomes. The self-management strategy is analogous to
diabetes care in patients who regulate prescribed therapy
using objective daily measurements of therapeutic efficacy
by the use of a glucometer. The modern strategy of con-
gestion management includes: treat filling pressures that go
up (hit the peaks) and treat to reduce chronically elevated
filling pressures even without acute change (hit the plateaus)
seeking to adjust diuretics up and down (during dry spells)
and empower the patient to make daily changes. Thus, a
lower risk of rehospitalization will depend on early clinic
follow-up post-discharge (within 7–10 days) and on per-
sonalized and frequent subsequent visits. At each follow-up
visit, fluid status and body weight should be monitored by
physical examination, bioimpedance and/or clinical scores
(reassessment of signs/symptoms). In addition, when possi-
ble, IVC, PCWP or E/e1 (echocardiographic evaluation) and
ultrasound B lines should be performed too. The steps of this
personalized and congestion-oriented approach are summa-
rized in Fig. 4 and include new technological advances such
as the home telemonitoring and electronic assessment of
weight, HF symptoms and thoracic impedance by devices
and pressure sensors.
Dietary Sodium and Water intake in Heart Failure
All HF management guidelines recommend sodium
restriction as a key factor in optimizing fluid balance;
however, there are insufficient data to endorse any spe-
cific level of sodium intake with certainty, and differences
among the various HF subpopulations are not known. The
Heart Failure Society of America recommends
2,000–3,000 mg daily sodium intake for patients with the
clinical syndrome of HF and preserved or depressed
ejection fraction, with further restriction (\2,000 mg) for
moderate to severe HF and patients with recurrent or
refractory volume overload. European Guidelines indicate
restriction of sodium intake to \2,000 mg/day in symp-
tomatic patients. However, the level of restriction is
controversial [43]. An observational cohort study in the
Second and Third National Health and Nutrition Exami-
nation Survey (NHANES) showed an association between
low sodium intake and cardiovascular mortality [44].
O’Donnell et al. [45] found a J-shaped association
between estimated sodium excretion and CV events with
the possibility of increased risk of CVD morbidity and
mortality at both extremes of sodium intake. Compared
with baseline sodium excretion of 4–5.99 g per day,
sodium excretion of more than 7 g per day was associated
with an increased risk of all CV events while a sodium
excretion of \3 g per day was associated with increased
risk of CV mortality and hospitalization for HF. Thus,
there is some evidence for a ‘‘J’’ curve fit, with a safe zone
of about 2.5–6.0 g/day [43].
In compensated HF patients receiving high-dose oral
furosemide, it has been found that sodium restriction to
80 mmol/day (1,840 mg/day) was associated long term
with significantly higher rates of hospitalization and
increased levels of BNP, aldosterone, plasma renin activity
and cytokines (TNF-a, IL-6) compared with those patients
receiving less restricted sodium intake of 120 mmol/day
(2,760 mg/day) who showed improvement in clinical
compensation, neurohormonal and inflammatory activa-
tion, and outcome [46]. These findings were recently sup-
ported by a Cochrane review which showed that sodium
reduction resulted in a significant increase in plasma renin,
plasma aldosterone, plasma adrenaline and plasma nor-
adrenaline [47]. Recently, Lennie et al. [48] interestingly
showed \3,000 mg/d sodium was associated with better
outcomes in NYHA class III to IV patients, whereas it was
associated with significant increase in hospital visits,
readmissions, and mortality in NYHA class I–II patients.
All these data, in addition to recent data concerning the
utility of hypertonic saline in decompensated HF, do not
support universal strict sodium restriction in HF patients
and indicates the need to define a safe range of sodium
20 Heart Fail Rev (2015) 20:13–24
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intake in this setting, recalling the experience with b-
blockers which were previously contraindicated in HF.
Regarding fluid restriction, international guidelines
recommend fluid restriction of 1.5–2 liters/day during the
initial management of an acute episode of HF associated
with volume overload in symptomatic patients with severe
hyponatremia \130 mEq/L and in all symptomatic
subjects demonstrating fluid retention that is difficult to
control despite high doses of diuretic and sodium restric-
tion. More strict fluid restriction is recommended in
patients with more severe hyponatremia (serum sodium
\125 mEq/L) although the data are not conclusive. Many
practices have found it impractical and unpleasant to
restrict fluid to \2 L daily. Aliti et al. [49] observed in
Fig. 4 Congestion-guided
clinical approach and decision-
making during post-discharge
follow-up of patients with HF
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systolic ADHF patients with normal serum sodium that
aggressive fluid (\800 ml/day) and sodium restriction
(800 mg/day) when compared with diet without restriction
have no differences on weight loss, clinical stability and
30-day readmission rate. Conversely, some new evidences
suggest that fluid restriction to 1 L or less in addition to
near-normal sodium diet may be useful in during inter-
mediate term follow-up in recently decompensated HF
patients without hyponatremia and might be considered by
highly motivated patients who undergo frequent or per-
sistent fluid overload despite optimized flexible diuretic
regimens [46, 49–53]. Probably, the discrepancy in these
results may depend on the different sodium diet strategy
rather than fluid regimen.
Conclusions
The major goal in patients hospitalized with HF is to decrease
the burdens of symptoms that limit daily life and lead to re-
hospitalization. A primary aim of initial and serial evaluation
of patients with HF remains the identification of congestion
and increased intra-cardiac pressures. The mandatory next
step is to prevent or relieve chronic fluid overload, to pre-
serve or achieve a dry clinical profile, and to maintain low
BNP levels and intra-cardiac pressures without significant
worsening of renal function. However, we are still failing to
recognize and treat congestion largely because elevations of
intra-cardiac pressures can occur well before obvious clinical
signs/symptoms develop or because clinical signs/symptoms
are underestimated. Fortunately, new and accurate strategies
for monitoring congestion are now available. Every patient
with suspected or evident congestion should undergo careful
individualized assessment with serial evaluation that includes
medical history, physical examination for congestion which
may be supplemented by serial measurements of BNP,
echocardiographic assessments of filling pressures and pul-
monary interstitial edema, and measurements of ventilatory
flows in order to unmask central fluid overload or to better
monitor congestion before clinical signs/symptoms become
evident (Fig. 3). Clinical surveillance after hospitalization
with an optimized post-discharge follow-up planning is
mandatory in HF management. The critical elements in this
setting include frequent and personalized ambulatory visits
including telephone monitoring and ‘‘telemedicine’’, a tai-
lored congestion-guided treatment regimen (dynamic diure-
tic titration beginning from low to high doses and eventual
controlled dose reduction when a clinical steady state is
reached), a controlled fluid and salt intake plan, renal func-
tion monitoring with traditional and novel biomarkers, and an
organized network between the primary care provider, car-
diologist, hospitalist and nurses. When clinical and nonin-
vasive assessments fail to explain symptoms or lead to
therapy that is poorly tolerated, consideration should be
given to the possibility of R-L mismatch and other contri-
butions to symptoms such as intrinsic pulmonary disease and
the possible need for invasive hemodynamic measurement
for clarification [11]. Further clinical studies are needed to
recognize the submerged iceberg of congestion and its
pathophysiological mechanisms at improving HF manage-
ment and outcome.
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